tetano
Editor, Senior Moderator
BMC Infect Dis
. 2021 Aug 30;21(1):887.
doi: 10.1186/s12879-021-06602-w.
Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial
Nobuhisa Ishiguro[SUP] 1 [/SUP], Yoichi M Ito[SUP] 2 [/SUP], Sumio Iwasaki[SUP] 3 [/SUP], Miki Nagao[SUP] 4 [/SUP], Hideki Kawamura[SUP] 5 [/SUP], Shinichiro Kanai[SUP] 6 [/SUP], Yoko Nukui[SUP] 7 [/SUP], Koichi Tokuda[SUP] 8 [/SUP], Takayuki Miyara[SUP] 9 [/SUP], Hidetoshi Igari[SUP] 10 [/SUP], Koichi Yamada[SUP] 11 [/SUP], Hiroki Chikumi[SUP] 12 [/SUP], Chiaki Sano[SUP] 13 [/SUP], Ryuji Koike[SUP] 7 [/SUP], Tetsuya Yagi[SUP] 14 [/SUP], Nobuo Murakami[SUP] 15 [/SUP], Japan Infection Prevention, Control Conference for National, Public University Hospitals
Affiliations
Abstract
Background: In a previous retrospective observational study, a 3-day regimen of oseltamivir as post-exposure prophylaxis (PEP) for preventing transmission of influenza in wards was shown to be comparable to 7- to 10-day regimens provided index cases were immediately separated from close contacts. In order to confirm the efficacy of a 3-day regimen, we started to conduct a prospective, multi-center, single-arm trial.
Methods: This study is a prospective, multi-center, single-arm study designed by the Sectional Meeting of Clinical Study, Japan Infection Prevention and Control Conference for National and Public University Hospitals. Index patients with influenza are prescribed a neuraminidase inhibitor and are discharged immediately or transferred to isolation rooms. The close contacts are given oseltamivir as 75 mg capsules once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children for 3 days as PEP. All close contacts are monitored for development of influenza for 7 days after starting PEP.
Discussion: A 3-day regimen of oseltamivir as PEP has advantages over 7- to 10-day regimens in terms of costs, medication adherence and adverse effects. Trial registration The Institutional Review Board of Hokkaido University Hospital for Clinical Research, 015-0518, registered on November 11, 2016. UMIN Clinical Trials Registry, UMIN000024458, disclosed on October 31, 2016. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027881 . Japan Registry of Clinical Trials, jRCTs011180015, disclosed on March 14, 2019. https://jrct.niph.go.jp/latest-detail/jRCTs011180015.
Keywords: Hospital wards; Influenza; Oseltamivir; Post-exposure prophylaxis.
. 2021 Aug 30;21(1):887.
doi: 10.1186/s12879-021-06602-w.
Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial
Nobuhisa Ishiguro[SUP] 1 [/SUP], Yoichi M Ito[SUP] 2 [/SUP], Sumio Iwasaki[SUP] 3 [/SUP], Miki Nagao[SUP] 4 [/SUP], Hideki Kawamura[SUP] 5 [/SUP], Shinichiro Kanai[SUP] 6 [/SUP], Yoko Nukui[SUP] 7 [/SUP], Koichi Tokuda[SUP] 8 [/SUP], Takayuki Miyara[SUP] 9 [/SUP], Hidetoshi Igari[SUP] 10 [/SUP], Koichi Yamada[SUP] 11 [/SUP], Hiroki Chikumi[SUP] 12 [/SUP], Chiaki Sano[SUP] 13 [/SUP], Ryuji Koike[SUP] 7 [/SUP], Tetsuya Yagi[SUP] 14 [/SUP], Nobuo Murakami[SUP] 15 [/SUP], Japan Infection Prevention, Control Conference for National, Public University Hospitals
Affiliations
- PMID: 34461842
- DOI: 10.1186/s12879-021-06602-w
Abstract
Background: In a previous retrospective observational study, a 3-day regimen of oseltamivir as post-exposure prophylaxis (PEP) for preventing transmission of influenza in wards was shown to be comparable to 7- to 10-day regimens provided index cases were immediately separated from close contacts. In order to confirm the efficacy of a 3-day regimen, we started to conduct a prospective, multi-center, single-arm trial.
Methods: This study is a prospective, multi-center, single-arm study designed by the Sectional Meeting of Clinical Study, Japan Infection Prevention and Control Conference for National and Public University Hospitals. Index patients with influenza are prescribed a neuraminidase inhibitor and are discharged immediately or transferred to isolation rooms. The close contacts are given oseltamivir as 75 mg capsules once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children for 3 days as PEP. All close contacts are monitored for development of influenza for 7 days after starting PEP.
Discussion: A 3-day regimen of oseltamivir as PEP has advantages over 7- to 10-day regimens in terms of costs, medication adherence and adverse effects. Trial registration The Institutional Review Board of Hokkaido University Hospital for Clinical Research, 015-0518, registered on November 11, 2016. UMIN Clinical Trials Registry, UMIN000024458, disclosed on October 31, 2016. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027881 . Japan Registry of Clinical Trials, jRCTs011180015, disclosed on March 14, 2019. https://jrct.niph.go.jp/latest-detail/jRCTs011180015.
Keywords: Hospital wards; Influenza; Oseltamivir; Post-exposure prophylaxis.